Orsa
VC Fund
Marche-en-famenne, Belgium
Orsa is a capital firm that works on investments in different industries including food, general industry, and technological startup.
- Total investments:
- 14
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Orsa invests in
Stages Orsa invests in
Countries Orsa invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Seed
- $546k–$24M
- Series A
- $4.7M–$29M
- Series B
- $22M–$23M
Investment Focus
Industry
- Biotechnology 5 (36%)
- Medical 3 (21%)
- Health Care 3 (21%)
- Internet 2 (14%)
- Therapeutics 2 (14%)
Stage
- Series A 5 (36%)
- Seed 4 (29%)
- Series B 1 (7%)
- Funding Round 1 (7%)
- Convertible Note 1 (7%)
Country
- Belgium 8 (57%)
- France 3 (21%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Benoit Coppée
President & CEO
|
President & CEO | Total investments: 0 | Find email | |
Christophe Fruytier
Administrateur
|
Administrateur | Total investments: 0 | Find email | |
|
Gilles Koestel
Operational Manager,Partner
|
Operational Manager,Partner | Total investments: 1 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Novadip Biosciences, an advanced biopharmaceutical company focused on new generation of therapies from adipose stem cells adapted to hard and soft tissues reconstruction. | $11.9M / Convertible Note / Sep 21, 2026 | ||
| Brenus Pharma is an allogeneic platform to generate immune therapy ambitioning to harness patient immune system & prevent cancer resistance over treatment. | $12.6M / Series A / Jul 20, 2026 | ||
| Enodia Therapeutics is a biotech company that provides transforming treatments for cancer, inflammation, and viral infection diseases. | $24.2M / Seed / Jan 08, 2026 | ||
| Sunrise aims to bring simple answers to millions of people suffering from sleep disorders.We have developed a 3-gram sensor to diagnose sleep with gold standard quality. The technology offers a revolutionary new way to measure brain commands at night, with published clinical results never seen before. Studies demonstrate Sunrise is as accurate asin-lab sleep studies, at a fraction of the cost.Affecting one in three people, sleep disorders are extremely common. Sleep apnea is the most prevalent disease with almost 1 billion persons concerned. This condition leads to great body damage over time and yet remains undiagnosed in 80% of the cases.Patients, caregiver and insurers stand to benefit greatly from a solution to current highly cumbersome, expensive and time-consuming diagnostics systems. | $29.2M / Sep 25, 2025 | ||
| TrustUp is the home contractors platform, connects homeowners with verified quality home improvement. | $5.2M / Series A / Jan 01, 2025 | ||
| Brenus Pharma is an allogeneic platform to generate immune therapy ambitioning to harness patient immune system & prevent cancer resistance over treatment. | $25M / Series A / Sep 18, 2024 | ||
| Myocene is a Liège-based sports technology company which creates unique and innovative devices for measuring muscle fatigue and performance. | $3.2M / Seed / Jun 18, 2024 | ||
| AbolerIS Pharma aims to develop novel and unique therapeutic approaches to induce immune tolerance. | $29.2M / Series A / Sep 18, 2023 | ||
| Specialized in Web Intelligence (collecting, searching and filtering web information). Help companies and organizations to take advantage of Web information that are relevant to their development. Develops and commercializes Cikisi WMT, a Web Intelligence Solution. | $2.9M / Seed / Sep 01, 2023 | ||
| Curvo is an investment app that improves the financial well-being of the next generation of Europeans through the power of index investing. A young European can create an account in a few minutes and invest in a diversified portfolio of index funds that is tailored to their goals and personality. We take care of all the complexities related to(good) investing, and starting from €50, it's accessible to anyone. It's the easiest app for a young European to prepare for their future. | $545.8K / Seed / Jun 28, 2023 | ||
| See all 14 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Orsa invest in?
Orsa invests primarily in Biotechnology, Medical and Health Care startups, most often at Series A and Seed stage. Most of the 14 investments tracked by Shizune back companies in Belgium. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does Orsa invest in?
Orsa typically joins rounds of $546k–$24M at Seed, $4.7M–$29M at Series A and $22M–$23M at Series B. These are whole funding-round sizes, not Orsa's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds Orsa took part in.
How do I contact Orsa?
Public channels for Orsa include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Orsa?
The team at Orsa includes Benoit Coppée (President & CEO), Christophe Fruytier (Administrateur) and Gilles Koestel (Operational Manager,Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
